ISA Pharmaceuticals And Cancer Focus Fund Announce $5 Million Investment To Support First- In-Human Trial Of ISA’s Novel Immunotherapy ISA103 In Uveal Melanoma by rpadmin | Jan 4, 2023 | ISA